Published in CMAJ on September 08, 2005
A primary care-based interdisciplinary team approach to the treatment of chronic pain utilizing a pragmatic clinical trials framework. Transl Behav Med (2012) 0.86
A new extended release formulation (OROS) of hydromorphone in the management of pain. Ther Clin Risk Manag (2009) 0.75
Controlled-release opioids and alcohol. CMAJ (2006) 0.75
Tips for learning and teaching evidence-based medicine: introduction to the series. CMAJ (2004) 3.23
Risperidone (Risperdal): increased rate of cerebrovascular events in dementia trials. CMAJ (2002) 2.41
Herbal kava: reports of liver toxicity. CMAJ (2002) 2.17
Concerns over lindane treatment for scabies and lice. CMAJ (2003) 2.01
Droperidol: cardiovascular toxicity and deaths. CMAJ (2002) 1.68
Rosiglitazone (Avandia) and pioglitazone (Actos) and heart failure. CMAJ (2002) 1.64
Open Medicine's ghost and guest authorship policy. Open Med (2010) 1.62
Cochlear implant recipients at risk for meningitis. CMAJ (2002) 1.61
Global injury and violence. CMAJ (2006) 1.52
Rosiglitazone (Avandia) and macular edema. CMAJ (2006) 1.50
A catalyst for change. CMAJ (2006) 1.48
Olanzapine (Zyprexa): increased incidence of cerebrovascular events in dementia trials. CMAJ (2004) 1.43
Congratulations to our colleagues at Open Medicine. CMAJ (2007) 1.39
Brief safety updates: acetaminophen, ASA and kava. CMAJ (2002) 1.38
New restrictions on celecoxib (Celebrex) use and the withdrawal of valdecoxib (Bextra). CMAJ (2005) 1.29
Medical research and social media: Can wikis be used as a publishing platform in medicine? Open Med (2009) 1.27
Too much of a good thing? Toxic effects of vitamin and mineral supplements. CMAJ (2003) 1.27
Propofol: contraindicated for sedation of pediatric intensive care patients. CMAJ (2002) 1.25
Diane-35 (cyproterone acetate): safety concerns. CMAJ (2003) 1.22
Open Medicine is indexed in PubMed. Open Med (2010) 1.18
What's all the fuss? Safety concerns about COX-2 inhibitors rofecoxib (Vioxx) and celecoxib (Celebrex). CMAJ (2002) 1.18
Challenges of tuberculosis control. CMAJ (2006) 1.13
Open science, open access and open source software at Open Medicine. Open Med (2008) 1.06
Paroxetine (Paxil) and congenital malformations. CMAJ (2005) 1.03
No budget, no worries: Free and open source publishing software in biomedical publishing. Open Med (2008) 1.00
Salmeterol (Serevent) asthma trial halted early. CMAJ (2003) 0.99
Bupropion (Zyban, Wellbutrin SR): reports of deaths, seizures, serum sickness. CMAJ (2002) 0.99
Rosuvastatin (Crestor) and rhabdomyolysis. CMAJ (2004) 0.97
Increased mortality among elderly patients with dementia using atypical antipsychotics. CMAJ (2005) 0.94
Eczema drugs tacrolimus (Protopic) and pimecrolimus (Elidel): cancer concerns. CMAJ (2005) 0.93
Tamoxifen for breast cancer prevention: safety warning. CMAJ (2002) 0.92
Obesity drug sibutramine (Meridia): hypertension and cardiac arrhythmias. CMAJ (2002) 0.90
Antipsychotic clozapine (Clozaril): myocarditis and cardiovascular toxicity. CMAJ (2002) 0.90
Poverty and health. CMAJ (2006) 0.90
Facts on mercury and fish consumption. CMAJ (2002) 0.88
Visual loss with erectile dysfunction medications. CMAJ (2006) 0.88
Paroxetine (Paxil, Seroxat): increased risk of suicide in pediatric patients. CMAJ (2003) 0.88
Ephedra/ephedrine: cardiovascular and CNS effects. CMAJ (2002) 0.88
HIV drug stavudine (Zerit, d4T) and symptoms mimicking Guillain-Barré syndrome. CMAJ (2002) 0.87
Noninvasive treatments for umbilical granulomas. Am Fam Physician (2003) 0.85
Legionella infection. CMAJ (2005) 0.84
Long-acting beta2-agonists in asthma: safety concerns. CMAJ (2005) 0.84
Diabetes drug pioglitazone (Actos): risk of fracture. CMAJ (2007) 0.83
Failure of rapid HIV tests. CMAJ (2002) 0.83
Suicidal ideation among children taking atomoxetine (Strattera). CMAJ (2005) 0.83
Accutane (isotretinoin) and psychiatric adverse effects. CMAJ (2003) 0.83
People with diabetes should avoid antibiotic gatifloxacin. CMAJ (2006) 0.82
Striving for excellence: developing a framework for the Triple C curriculum in family medicine education. Can Fam Physician (2012) 0.82
The Canadian Hypertension Education Program (CHEP) recommendations: launching a new series. CMAJ (2005) 0.82
Septic shock after medical abortions with mifepristone (Mifeprex, RU 486) and misoprostol. CMAJ (2005) 0.82
A smouldering epidemic. CMAJ (2006) 0.81
Infliximab and serious hematologic events. CMAJ (2004) 0.80
She's dying for help: global HIV. CMAJ (2006) 0.80
Medications for attention deficit hyperactivity disorder: cardiovascular concerns. CMAJ (2006) 0.80
Taking away the sting of malaria. CMAJ (2006) 0.80
Patients receiving intravenous bisphosphonates should avoid invasive dental procedures. CMAJ (2005) 0.79
Asthma drug zafirlukast (Accolate): serious hepatic events. CMAJ (2004) 0.79
Mefloquine: contraindicated in patients with mood, psychotic or seizure disorders. CMAJ (2002) 0.79
Is waist-to-hip ratio a better marker of cardiovascular risk than body mass index? CMAJ (2006) 0.78
Medroxyprogesterone acetate (Depo-Provera) and bone mineral density loss. CMAJ (2005) 0.78
Oseltamivir (Tamiflu) unsafe in infants under 1 year old. CMAJ (2004) 0.78
HIV drug nevirapine (Viramune): risk of severe hepatotoxicity. CMAJ (2004) 0.78
Trastuzumab (Herceptin) and HER2-positive breast cancer. CMAJ (2006) 0.77
Nephrology in practice: a new series. CMAJ (2002) 0.77
Tegaserod (Zelnorm) for irritable bowel syndrome: reports of serious diarrhea and intestinal ischemia. CMAJ (2004) 0.76
Osteoporosis treatment: raloxifene (Evista) and stroke mortality. CMAJ (2006) 0.76
Triptan migraine treatments and antidepressants: risk of serotonin syndrome. CMAJ (2006) 0.75
Several Chinese herbal products may contain toxic aristolochic acid. CMAJ (2004) 0.75
Meniscus. CMAJ (2002) 0.75
Open Medicine at five years. Open Med (2012) 0.75
Ototoxic effects from gentamicin ear drops. CMAJ (2002) 0.75
Up close and personal: poverty and human development. Open Med (2007) 0.75
Medical gels and the risk of serious infection. CMAJ (2004) 0.75
The Evra (ethinyl estradiol/norelgestromin) contraceptive patch: estrogen exposure concerns. CMAJ (2005) 0.75
Hua Fo tablets tainted with sildenafil-like compound. CMAJ (2002) 0.75
West Nile virus. CMAJ (2005) 0.75
Nail gun. CMAJ (2002) 0.75
'Tis the season: meningococcal disease. CMAJ (2005) 0.75
Combination hormone replacement therapy and dementia. CMAJ (2003) 0.75
Persistent pulmonary hypertension of the newborn and maternal use of SSRIs. CMAJ (2006) 0.75
WinRho and disseminated intravascular coagulopathy. CMAJ (2006) 0.75
Do ASA and NSAIDs reduce the risk of colorectal cancer? CMAJ (2005) 0.75
Chewing the fat on trans fats. CMAJ (2005) 0.75
Does sex affect how patients respond to ASA? CMAJ (2006) 0.75
Earlier clinical conundrum resolved: a diagnosis with teeth. CMAJ (2005) 0.75
Opening Pandora's box: the public declaration of competing interests. Open Med (2010) 0.75
HIV screening. CMAJ (2005) 0.75
Is the timing of infant cereal introduction a risk factor for celiac disease autoimmunity? CMAJ (2005) 0.75
Serious allergic reactions following tuberculin skin tests. CMAJ (2005) 0.75
Finding healing hands: the global health workforce shortage. Open Med (2008) 0.75
Patient information about HPV and the HPV vaccine. CMAJ (2007) 0.75
Is watchful waiting a reasonable approach for men with minimally symptomatic inguinal hernia? CMAJ (2006) 0.75
Australia's MDs decry poor state of Aboriginal health. CMAJ (2003) 0.75
Advisers to the nation. CMAJ (2005) 0.75
Leaders or followers? It's time for health faculty to open up. Open Med (2008) 0.75
Epoetin alfa (Eprex): reports of pure red blood cell aplasia. CMAJ (2002) 0.75
"Unrealistic" to share North American antiviral supply. CMAJ (2005) 0.75
Lillian. CMAJ (2005) 0.75